Shots: Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA, will receive compensation of ~$10M & average of $67M/year in 2021 and […]readmore
Tags : Multi-Year
Shots: AbCellera to receive upfront, pre-clinical, clinical & commercial milestones including research payments for the non-COVID-19 targets plus royalties on future sales. Eli Lilly to get rights to develop and […]readmore
Shots: The companies allied to support Takeda’s research stage gene therapy discovery programs across its core therapeutic areas i.e. oncology, rare diseases, neuroscience and gastroenterology The collaboration leverages s Evotec’s […]readmore
Shots: The companies signed a multi-year, multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology The collaboration leverages H2L2 Harbour Mice platform to […]readmore
Shots: Veracyte collaborates with Acerta Pharma, a hematology research and development of AstraZeneca for providing genomic information for supporting development of oncology therapeutics On Dec 03, 2019 the company reported […]readmore
Shots: Beacon will take care of drug discovery activities while Arena will focus on development and commercialization of products for multiple immune and inflammatory diseases The focus of the agreement […]readmore
Shots: The companies collaborated to establish a Virtual Research and Development Center, enabling data sharing and analysis and focusing on research of therapies for multiple types of cancers, including gastrointestinal […]readmore
Shots: Cancer Research and LifeArc to receive upfront, milestones and royalties on sales of products. Ono to get an option to license the developed product with exclusive WW commercialization rights […]readmore
Shots: The companies collaborated to develop and commercialize novel in vivo delivery of CRISPR/Cas9 using ProBioGen’s technology. CRISPR Therapeutics also holds an option to license the developed product The focus […]readmore
Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The […]readmore